ACADIA to Host Conference Call and Webcast on Wednesday, August 8,2018, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Jul. 30, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its financial results for the secondquarter ended June 30, 2018 on Wednesday, August 8, 2018, after the U.S.financial markets close. ACADIA’s management will host a conference calland webcast on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time todiscuss ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 7987107). A telephone replayof the conference call may be accessed through August 22, 2018 bydialing 855-859-2056 for callers in the United States or Canada and404-537-3406 for international callers (reference passcode 7987107). Theconference call also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until August 22,2018.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceuticalcompany focused on the development and commercialization of innovativemedicines to address unmet medical needs in central nervous systemdisorders. ACADIA has developed and is commercializing the first andonly medicine approved for the treatment of hallucinations and delusionsassociated with Parkinson’s disease psychosis. In addition, ACADIA hasongoing clinical development efforts in additional areas withsignificant unmet need including dementia-related psychosis,schizophrenia inadequate response, schizophrenia-negative symptoms andmajor depressive disorder. This press release and further informationabout ACADIA can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press releasethat are not strictly historical in nature are forward-lookingstatements. These statements include but are not limited to statementsregarding the timing of future events. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2017 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
ElenaRidloff, CFA
(858) 558-2871
ir@acadia-pharm.com